The share capital increase pertaining to the 7,700,00 new shares was registered in the Norwegian Register of Business Enterprises yesterday. Following the registration, the share capital of Genetic Analysis AS is NOK 14,949,787.20 divided on 24,916,312 shares, each with a nominal value of NOK 0.60. In addition, 10,010,000 warrants have been issued.

The first day of trading in the shares on Spotlight Stock Market is expected to be on Friday 1 October 2021 under the ticker "GEAN".

For more information, please contact:
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com

About Genetic Analysis 

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development.  The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com